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Abstract
Background: Based on a large, representative unscreened cohort from Malmö, Sweden, we have
recently reported that a single prostate-specific antigen (PSA) measurement at or before age 50 is
a strong predictor of prostate cancer occurring up to 25 years subsequently. We aimed to
determine whether this association holds for advanced cancers, defined as clinical stage T3 or
higher, or skeletal metastasis at the time of the cancer diagnosis.
Methods: In 1974–1986 blood samples were obtained from a cohort of 21,277 men aged up to
50. Through 1999, 498 men were diagnosed with prostate cancer, and of these 161 had locally
advanced or metastatic prostate cancers. Three controls, matched for age and date of
venipuncture, were selected for each case. Conditional logistic regression was used to test
associations between molecular markers and advanced cancer.
Results: Median time from venipuncture to diagnosis was 17 years. Levels of all PSA forms and
hK2 were associated with case status. Total PSA was a strong and statistically significant predictor
of subsequent advanced cancer (area under the curve 0.791; p < 0.0005). Two-thirds of the
advanced cancer cases occurred in men with the top 20% of PSA levels (0.9 ng/ml or higher).
Conclusion: A single PSA test taken at or before age 50 is a very strong predictor of advanced
prostate cancer diagnosed up to 25 years later. This suggests the possibility of using an early PSA
test to risk-stratify patients so that men at highest risk are the focus of the most intensive screening
efforts.
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Background
We have previously shown that a single prostate-specific
antigen (PSA) measurement taken at age 50 or younger is
a strong predictor of prostate cancer diagnosed up to 25
years subsequently [1]. Our study cohort was obtained
from the Malmö Preventive Medicine Study, a large, rep-
resentative, population-based study on cardiovascular risk
factors that took place in Malmö, Sweden from 1974 to
1986. Using a case-control design, we found that PSA lev-
els in the archived blood plasma taken during 1974–1986
were significantly higher in men subsequently diagnosed
with prostate cancer compared with matched controls. As
the rate of PSA screening in Sweden during the study
period was very low [2], the study constitutes a 'natural
experiment' to test hypotheses about the development of
prostate cancer.
Our finding has several implications, most notably that a
single PSA test at age 45–50 could risk-stratify the popula-
tion for the intensity of subsequent screening. However,
as is well known, more men die with prostate cancer than
from prostate cancer, and many prostate cancers affect
neither the length nor the quality of a man's life. For
example, autopsy studies of men who die from causes
other than prostate cancer have found cancer in the pros-
tates of approximately 20% of men at age 60 and approx-
imately 40% at age 70 [3,4]; this sharply contrasts with the
low lifetime risk of dying from this disease. Moreover, in
contrast to the very marked country-to-country differences
in prostate cancer incidence, there is relatively minor var-
iation in prostate cancer mortality rates [5]. These obser-
vations raise the possibility that the sort of cancers
predicted by an early elevation of PSA might have little
clinical relevance.
Accordingly, we decided to reanalyze our data to focus on
an endpoint of unquestionable clinical significance:
locally advanced or metastatic disease at the time of pros-
tate cancer diagnosis. Skeletal metastases cause symp-
toms, such as pain, and most men with metastases die of
their disease [6,7]; as regards clinical stage T3, cancer that
has demonstrably grown outside the confines of the pros-
tate will, if left untreated, inevitably lead to severe disease
symptoms (e.g. local obstruction) or prostate cancer
metastasis [8]. In this study, we aimed to determine
whether levels of prostate-specific kallikreins (total PSA,
free PSA and hK2) measured in anti-coagulated plasma
samples could predict locally advanced or metastatic pros-
tate cancer up to 25 years before diagnosis. We also inves-
tigated whether combining different markers into a single
multivariable model could improve our ability to predict
compared to use of total PSA alone.
Methods
Study cohort and controls
Subjects, matching and analytical methods of the Malmö
Preventive Medicine study have been thoroughly
described in previous reports [1]. The Malmö Preventive
Medicine study was approved by the Ethics Committee at
Lund University and was, in brief, conducted from 1974
to 1986 by inviting men born between 1926 and 1949 to
participate in a study intended to primarily investigate risk
factors for major cardiovascular and metabolic diseases
[9]. EDTA-anticoagulated blood plasma samples were
archived at -20° and never thawed until the recent analy-
sis. Our analysis focused on those participants aged 33–50
at baseline, totaling 21,277 (74% of men invited).
According to the Swedish Cancer Registry, 498 (2.3%) of
these men were diagnosed with prostate cancer up to 31
December 1999. Blood samples were available and ana-
lyzable for 462 of these men (93%). In a majority of the
cases sextant biopsies were performed and evaluated
according to the Gleason system, but some were graded
according to World Health Organization (WHO) criteria.
Therefore, to obtain a homogenous description of our
cohort, we translated all tumor grades into the WHO sys-
tem. Data on bone scans at the time of diagnosis were
available for 370 (80%) of 462 men; clinical stage data
were available for 398 (86%).
We used a case-control study design nested within the
Malmö Preventive Project cohort. Participants without a
prostate cancer diagnosis at the study close date were
matched with cases for age and date of baseline venipunc-
ture (± 3 months for both factors for ~95% of controls).
Controls were then randomly selected from matches. The
present investigation included only those cases with
advanced prostate cancer and their respective controls.
Advanced prostate cancer was defined as metastases veri-
fied by bone scan or clinical stage at least T3 at the time of
prostate cancer diagnosis.
There were 161 cases in the study. Although three controls
were initially matched for each case, we later found that
47 controls were not followed until diagnosis of the
matched case, usually because of early death, leaving 436
controls. Most cases had either two (24%) or three (73%)
matched controls; four cases (3%) had one control.
Almost all cases (152, 94%) were ages 40–50 at venipunc-
ture. The remaining nine cases were aged less than 40: the
ages of each of these patients at venipuncture and at diag-
nosis were 33/49, 35/53, 35/54, 36/51, 37/57, 37/57, 39/
53, 39/59 and 39/59. As age was a matching criterion, the
age distribution in controls was very similar.
PSA measurements
PSA was assayed in anticoagulated plasma stored at -20°C
for 17–28 years. Although PSA forms, particularly freeBMC Medicine 2008, 6:6 http://www.biomedcentral.com/1741-7015/6/6
Page 3 of 8
(page number not for citation purposes)
PSA, in serum are labile in some storage conditions, we
previously showed that the levels of both total PSA and
free PSA in anticoagulated plasma are unaffected by long-
term storage at -20°C [10]. The levels of total PSA, free
PSA and hK2 were measured in archived plasma from
cases and controls as described previously [1]. Levels of
complexed PSA were calculated as total PSA minus free
PSA. Total PSA measured by the assay used, Prostatus
Free/Total PSA assay (Perkin-Elmer Life Sciences Turku,
Finland), differs by 13% from WHO calibration standards
[11].
Statistical analysis
For our main analysis we defined an event as metastases
or clinical stage at least T3 at the time of prostate cancer
diagnosis. We conducted conditional logistic regression
based on matching for age and date of venipuncture to
determine associations between molecular markers and
the event. To calculate predicted probability of the event
among Swedish men for a given PSA level, we entered PSA
in a logistic model using restricted cubic splines with
knots at the tertiles. Owing to the 3:1 matched case-con-
trol design, the incidence of advanced cancer in our study
was close to 25%. To correct the incidence to the expected
probability at age 75, we adjusted the probabilities by
adding a constant (a Bayes factor) to the linear prediction.
The expected probability of advanced cancer at age 75 was
derived by taking the estimated probability of prostate
cancer by age 75 in Swedish men (10%) [12], and multi-
plying by the proportion of advancer cancer cases that
were observed in this cohort (i.e. number of advanced
prostate cancer cases/number of total prostate cancer
cases). These probabilities were determined among men
aged 44–50 at baseline, as this is just before the age at
which men are typically recommended to initiate prostate
cancer screening. All statistical tests were two-sided. All
analyses were conducted using Stata 9.2 (Stata Corp., Col-
lege Station, TX).
Results
There were 161 patients matching the criteria for
advanced prostate cancer for our main analysis, 62 with
skeletal metastases and 149 with clinical stage at least T3
at the time of prostate cancer diagnosis. Fifty patients had
both metastases and clinical stage at least T3. The median
time from baseline venipuncture to diagnosis was 17
years (interquartile range 15, 19), with median age at
diagnosis 64 years (interquartile range 60, 67). Eighteen
patients (11%) had WHO grade I disease, 73 patients
(45%) grade II and 69 patients (43%) grade III, with
WHO grade missing for one patient. Five (3%) patients
were clinically judged to have stage T1 disease, 7 patients
(4%) T2 and 149 patients (93%) T3–T4. Twelve (7%)
patients had lymph node metastases, 57 (35%) patients
did not and 92 patients were not evaluated for nodal sta-
tus.
Prostate-specific kallikrein measurements are reported in
Table 1 and illustrated in Figure 1. In the anti-coagulated
plasma collected at baseline, median levels of total PSA,
complexed PSA, free PSA and hK2 were higher, and
median free-to-total PSA ratio lower, for men who were
found to have skeletal metastases or clinical stage at least
T3 at the time of prostate cancer diagnosis, compared with
men not diagnosed with prostate cancer.
Table 2 shows the utility of various PSA forms to predict
risk of skeletal metastases or clinically advanced disease at
the time of prostate cancer diagnosis by univariate analy-
sis. All of the prostate-specific kallikreins were associated
with case status (all p < 0.0005). An increase of 1 ng/ml in
total PSA was associated with an odds ratio for advanced
cancer of 4.29 (95% confidence interval (CI) 2.98, 6.18).
Odds ratios from the multivariable model are not pre-
sented here because of high collinearity between the
markers: for example, the correlation between free and
total PSA was 0.963. To assess whether markers other than
total PSA could aid in discrimination of advanced cancer
(skeletal metastases or clinical stage at least T3 at diagno-
sis) from no cancer diagnosis, we calculated the area
under the curve (AUC) for all markers alone using ten-
fold cross-validation. Total PSA (AUC 0.791) and com-
plexed PSA (AUC 0.793) discriminated advanced cancer
from no cancer most strongly. We then fitted a multivari-
Table 1: Plasma levels of total PSA, PSA subforms and hK2 in cases and controls at baseline venipuncture. Data are given as median 
(interquartile range). For illustrative purposes, we show data for cases known to be less than T3 and M0 at diagnosis (88 cases had data 
missing for either stage or metastases and were not T3, T4 or M+). As would be expected, controls matched with non-advanced 
cancers had almost identical markers levels to the controls matched with advanced cases (data not shown).
Marker Advanced cancer n = 161 Controls (matched with advanced cases) 
n = 436
Non-advanced cancer n = 213
Total PSA (ng/ml) 1.22 (0.67, 2.42) 0.54 (0.36, 0.78) 0.98 (0.61, 1.56)
Free PSA (ng/ml) 0.35 (0.22, 0.67) 0.18 (0.12, 0.26) 0.30 (0.19, 0.45)
Complexed PSA (ng/ml) 0.81 (0.41, 1.64) 0.32 (0.20, 0.51) 0.62 (0.38, 1.04)
Free to total PSA ratio (%) 29.0 (24.2, 33.7) 32.7 (28.3, 37.2) 30.5 (26.2, 33.7)
Human kallikrein 2 (ng/ml) 0.039 (0.027, 0.055) 0.033 (0.023, 0.044) 0.037 (0.028, 0.053)BMC Medicine 2008, 6:6 http://www.biomedcentral.com/1741-7015/6/6
Page 4 of 8
(page number not for citation purposes)
able model consisting of total PSA, free PSA, free-to-total
PSA ratio and hK2; the AUC for this model was 0.785.
Hence, there was no evidence that the additional markers
added discriminative accuracy above that of total PSA
alone. We therefore focused on total PSA for the remain-
ing analyses.
Small increases in total PSA markedly increased the risk of
a subsequent diagnosis of advanced prostate cancer (Table
3). For example, a modestly increased total PSA level of
1.01–2 ng/ml raised the odds more than seven-fold com-
pared with a total PSA of 0.5 ng/ml or less, and the odds
increased 22-fold for a total PSA 2.01–3 ng/ml. To ensure
that our results are not explained purely by events occur-
ring shortly after venipuncture, we performed additional
analyses in subgroups based on time from venipuncture
to diagnosis (Table 4). Total PSA was a predictor of
advanced disease among men diagnosed 16–19 and 20
years or more following venipuncture (both p < 0.0005).
There was an apparent increase in odds ratio for diagnosis
after 20 years. We believe that this is a chance finding
related to chance differences in controls; the mean total
PSA in controls for patients diagnosed more than 20 years
following venipuncture was 0.56 ng/ml compared with
0.69 ng/ml in controls for patients diagnosed less than 20
years after venipuncture. Hence, although our data sup-
port the hypothesis that total PSA can predict advanced
prostate cancer at the time of diagnosis up to 25 years
later, we do not believe they can be used to suggest that
total PSA predicts later cancers more effectively than ear-
lier cancers.
Similar results were found for the other kallikreins: all but
hK2 (p = 0.06) remained statistically significant predictors
of advanced prostate cancer among men diagnosed at
least 20 years after venipuncture.
Table 3: Odds of advanced cancer at the time of diagnosis 
related to different levels of total PSA
Total PSA (ng/ml) Cases Controls Odds ratio 95% CI
0.00–0.50 22 204 Reference -
0.51–1.00 42 165 2.37 1.33, 4.23
1.01–2.00 45 55 7.25 3.89, 13.5
2.01–3.00 25 10 21.5 8.58, 53.8
3.01+ 27 2 120 26.0, 557
Box plot of total PSA, free-to-total PSA ratio and hK2 levels  separately for cases of advanced cancer and controls Figure 1
Box plot of total PSA, free-to-total PSA ratio and hK2 levels 
separately for cases of advanced cancer and controls.
Table 2: Univariate associations between molecular markers and 
advanced prostate cancer at the time of diagnosis. Advanced 
cancer was defined as skeletal metastases or clinical stage ≥ T3. 
Predictive accuracy of each marker is given as AUC. To facilitate 
comparisons between markers, the odds ratios are for an 
increase of one-quarter of a standard deviation.
Marker Odds ratio 95% CI AUC
Total PSA 3.19 2.38, 4.27 0.791
Free PSA 3.06 2.30, 4.08 0.776
Complexed PSA 3.11 2.33, 4.16 0.793
Percent free to total PSA 0.85 0.80, 0.90 0.641
Human kallikrein 2 1.25 1.13, 1.38 0.604BMC Medicine 2008, 6:6 http://www.biomedcentral.com/1741-7015/6/6
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Using the Bayesian approach described above, we esti-
mated the probability of advanced prostate cancer at the
time of diagnosis for different levels of total PSA in the
plasma obtained from the 142 cases (88%) and 382 con-
trols who were ages 44–50 at baseline venipuncture (Fig-
ures 2 and 3). For those with total PSA 0.5–1 ng/ml, the
risk of advanced prostate cancer was 2–4%, close to the
population mean risk of 3.5%. Subjects with a total PSA
of 2 ng/ml had a risk of advanced prostate cancer of 12%,
more than three times the population mean. Sixty-nine
(49%) of advanced cancers occurred among the 10% of
subjects with the highest PSA levels (total PSA at least 1.2
ng/ml), while 94 (66%) occurred among the top 20%
(total PSA at least 0.9 ng/ml).
Our results were based on the pre-specified definition of
advanced prostate cancer (skeletal metastasis or clinical
stage at least T3 at the time of prostate cancer diagnosis).
To check whether our results were sensitive to the defini-
tion of advanced cancer used, we performed additional
analyses with two different definitions. The first was more
inclusive, defining advanced prostate cancer as any of
skeletal metastasis, clinical stage at least T3, lymph node
involvement or WHO grade III at the time of prostate can-
cer diagnosis. The second was less inclusive and consid-
ered only presence of skeletal metastasis at diagnosis. This
did not have a major effect on any of the results: some key
statistics are shown in Table 5 for each definition of
advanced prostate cancer.
Discussion
The Malmö Preventive Medicine cohort was enrolled
before the PSA era, and there was no subsequent recom-
mendation for prostate cancer screening in this region.
The rate of PSA testing has accordingly remained very low
up to our current study endpoint [2]. Furthermore, the
participation rate (74%) was high and case ascertainment
was complete owing to the excellent coverage of the Swed-
ish National Cancer Registry [13]. Our study is therefore
not subject to the sort of verification and selection biases
commonly associated with prostate cancer studies and
provides a 'natural experiment' to test hypotheses con-
cerning the long-term prediction of prostate cancer.
Our results describe the relationship between prostate kal-
likreins in blood plasma obtained at a single occasion at
age 50 or below and the diagnosis of advanced prostate
cancer up to 25 years later. We found that prostate-specific
kallikreins were significantly increased decades before the
clinical manifestation of advanced disease. The predictive
accuracy of total PSA was very high (AUC 0.791). Mod-
estly increased levels of total PSA in the ranges of 1.01–2
ng/ml and 2.01–3 ng/ml were associated with 7- and 22-
fold elevated odds of advanced prostate cancer, respec-
tively. The majority of advanced cancers (66%) occurred
in the 20% of the population with the highest PSA levels.
It is also noteworthy that our study of archived blood
samples is taken from a highly representative, population-
based sample. There was no selection based on test results
Predicted probability of advanced prostate cancer by popula- tion-based centiles of PSA measured at age 44–50 Figure 3
Predicted probability of advanced prostate cancer by popula-
tion-based centiles of PSA measured at age 44–50. Dashed 
lines indicate the 95% CIs.
Table 4: Odds ratio for advanced prostate cancer diagnosis, 
calculated according to delay from baseline venipuncture to 
diagnosis. Odds ratios are for each 1 ng/ml increase in PSA.
Delay to diagnosis Cases Odds ratio 95% CI p-value
≤15 years 59 4.30 2.40, 7.72 <0.0005
16–19 years 63 3.05 1.85, 5.04 <0.0005
≥20 years 39 11.0 3.09, 38.9 <0.0005
All 161 4.29 2.98, 6.18 <0.0005
Predicted probability of advanced prostate cancer by the  total PSA level in anti-coagulated plasma measured at age 44– 50 Figure 2
Predicted probability of advanced prostate cancer by the 
total PSA level in anti-coagulated plasma measured at age 44–
50. Dashed lines indicate the 95% CIs.BMC Medicine 2008, 6:6 http://www.biomedcentral.com/1741-7015/6/6
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(indeed, this would not have been possible, as the PSA
test was not available during the period when bloods were
drawn). As such, we can be confident that our reported
test characteristics reflect those of the population to which
we would like to apply our results.
These results confirm our previous finding of an associa-
tion between PSA levels and subsequent prostate cancer,
and suggest that this association is not restricted to cancers
unlikely to affect a man's survival or quality of life.
Indeed, we found total PSA to be more strongly predictive
of subsequent advanced prostate cancer (AUC 0.791)
than of any prostate cancer (AUC 0.762). This illustrates
the rule of thumb that it is easier to predict more extreme
medical events. Free-to-total PSA ratio and hK2, two
markers associated more specifically with malignancy,
were far less predictive than total PSA, a marker associated
with both benign and malignant prostate conditions. This
suggests that PSA elevations in cases below or at age 50
may be related to a premalignant state, or to a carcino-
genic process, rather than the presence of malignant cells
in the prostate.
A possible limitation of our study is that any definition of
clinically significant prostate cancer is open to question.
However, we repeated our analysis altering our definition
of advanced cancer to be more restrictive (only patients
with skeletal metastases at diagnosis) or more inclusive
(skeletal metastases or clinical stage al least T3 or positive
lymph nodes or grade III at time of diagnosis) and found
no important differences in our results. It might also be
argued that death from prostate cancer would be the most
appropriate endpoint, but owing to a small number of
events in our current study cohort, statistical analysis
would have been underpowered. Future studies will
address the relationship between kallikreins and death
from prostate cancer as the cohort matures.
Previously, both our group and other investigators have
studied the association between PSA level in the blood
and the long-term risk of being diagnosed with any stage
of prostate cancer, but did not specifically address
whether these findings were applicable to diagnosis of
advanced tumors [1,14-16]. Our findings reconfirm previ-
ous analyses suggesting that prostate cancer can be pre-
dicted many years before it is diagnosed and that we
might therefore reduce prostate cancer mortality by inter-
vening at an early stage when curative treatment is still
possible.
Current US prostate screening guidelines recommend that
all men over age 50 who have a life expectancy of at least
10 years should have an annual digital examination and
PSA test. Results from ongoing screening trials show that
these recommendations result in over-diagnosis and over-
treatment. For example, the Rotterdam section of the
European Randomized Screening Study for Prostate Can-
cer have shown that almost 50% of screen-detected can-
cers are indolent (organ-confined, Gleason 6 or less, and
0.5 cc or less in volume) and thus unlikely to affect a
man's survival or quality of life [17]. Over-treatment is
associated not only with high morbidity, such as poor
erectile, bowel and urinary function resulting from sur-
gery or radiotherapy, but also high healthcare costs. A
screening program that focused on those at highest risk of
prostate cancer morbidity or mortality might well have a
superior benefit-to-harm ratio compared with the current
approach of screening all men. One scenario might be to
make exceptional efforts to ensure that all men obtain a
PSA test in their mid to late forties. Although a man with
a PSA elevated above the threshold for biopsy (e.g. 3 ng/
ml) could be referred for immediate biopsy, this would be
very rare (~1–2% in the current data set); the primary pur-
pose of the early PSA test would be to determine which
men should be invited back for regular screening at age 50
and which men advised that PSA screening is unlikely to
benefit them.
This study is based on a previously published case-control
study in which we attempted to predict the occurrence of
prostate cancer at any stage. We did not re-match for this
study and hence patients with a prostate cancer diagnosis
Table 5: Sensitivity analyses
















Metastases or ≥ 
T3
161/436 4.29 (2.98, 6.18) 0.92 (0.89, 0.95) 0.791 0.641 0.785
Less inclusive* 62/163 3.02 (1.87, 4.90) 0.90 (0.84, 0.95) 0.762 0.674 0.751
More inclusive† 190/512 4.05 (2.89, 5.67) 0.92 (0.89, 0.95) 0.782 0.645 0.780
* Presence of skeletal metastases at time of diagnosis.
† Presence of any of the following criteria at time of diagnosis: skeletal metastasis, clinical stage at least T3, positive lymph node, WHO grade III.BMC Medicine 2008, 6:6 http://www.biomedcentral.com/1741-7015/6/6
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were not included in the sample from which controls were
selected. We note that kallikrein levels of these 301 partic-
ipants are likely to be higher than those of Malmö Preven-
tive Medicine participants not diagnosed with prostate
cancer, thus inflating differences between cases and con-
trols in our current analysis. However, the original Malmö
Preventive Medicine cohort contains approximately
21,270 participants who could act as controls, from
whom 436 controls were randomly chosen to be included
in our current analysis. As there were 462 prostate cancer
cases, we would expect prostate cancer patients to com-
prise approximately 2% of the control group. Therefore,
we conclude that our failure to sample from non-
advanced prostate cancer cases is unlikely to have any
major effect on the current results.
Conclusion
A PSA level measured at a single occasion in blood drawn
at age up to 50 is a very strong predictor of being diag-
nosed with advanced prostate cancer up to 25 years later.
This raises the possibility that screening for prostate can-
cer could be risk-stratified so that men at highest risk are
the focus of the most intensive screening efforts.
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